[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619696":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":41,"responsibleParty":55,"collaborators":57,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":35,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":92,"whyStopped":35,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"First Affiliated Hospital of Ningbo University","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"lidocine infusion group","EXPERIMENTAL","Lidocaine is administered intravenously at an ideal body weight (IBW) of 1.5 mg\u002Fkg starting from anesthesia induction, for 10-20 minutes, and then continuously infused at 1-1.5 mg\u002Fkg\u002Fh until 1 hour after skin closure, with a maximum rate of 120 mg\u002Fh. Use ideal weight instead of actual weight to prevent toxicity in very overweight patients. In patients with a weight lower than the ideal weight, the actual weight should be used to calculate the dose.",[13],"Drug: Lidocaine (drug)",{"label":15,"type":16,"description":17,"interventionNames":18},"normal saline group","PLACEBO_COMPARATOR","The normal saline is administered at the volume calculated based on the equivalent volume of lidocaine dose according to body weight",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Lidocaine (drug)","According to the random number table, grouping and coding are set, and the coding rules are predetermined by the statistical analyst. The intervention information is placed in a sealed opaque envelope and managed by an independent randomization specialist. After signing the informed consent form, the randomization specialist will configure drugs based on the grouping information and label them with codes, and hand them over to the anesthesiologist conducting blind intervention operations",[9,15],[26],"Lidocaine IV",[28],{"name":29,"affiliation":5,"role":30},"Changshun Huang, MD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+8613957882779",null,"fyyhuangchangshun@nbu.edu.cn",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Yong Li","+8615168541165","yongli332603@163.com",[42],{"facility":43,"status":35,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":35},"The first affiliated hospital of Ningbo University","Ningbo","Zhejiang","315000","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.54945,29.87819,{"lat":53,"lon":52},{"type":30,"investigatorFullName":29,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"Departmental director",[58,61,63],{"name":59,"class":60},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",{"name":62,"class":60},"Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University",{"name":64,"class":65},"Ningbo Medical Center Lihuili Hospital","OTHER_GOV","100619696","lidocaine-decreases-postoperative-lung-cancer-reoccurance-and-metatasis-risk-100619696",false,"NCT07347977","Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk","Lidocaine Infusion Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk: a Multicenter Randomized Controlled Study","LidCRM","Inclusion Criteria:\n\n1. Age range: 18-80 years old.\n2. Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer\n3. Is willing and capable of providing consent.\n\nExclusion Criteria:\n\n1. Palliative surgery without intention of cure.\n2. Extensive comorbidities (ASA IV).\n3. Patients with known or suspected allergy to lidocaine.\n4. Patients who are currently pregnant or breastfeeding.\n5. Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.\n6. Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.\n7. Currently, there is severe renal insufficiency (serum creatinine ≥451umol\u002FL or glomerular filtration rate (calculated using the MDRD formula) \\\u003C30ml\u002Fmin).\n8. Epilepsy.\n9. Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.\n10. Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).\n11. Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.\n12. Patients with body weight \\\u003C40kg","ALL","18 Years","80 Years",{"count":78,"type":79},1400,"ESTIMATED","INTERVENTIONAL",[82],"NA","The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.\n\nParticipants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg\u002Fkg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg\u002Fkg\u002Fh (calculated as 1-1.5 mg\u002Fkg\u002Fh in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge",[85,86,87],"Non-Small Cell Lung Cancer","Recurrence","Survival Analysis",[89,90,86,91],"Lidocaine","Non-small cell lung cancer","Survival analysis","NOT_YET_RECRUITING","2026-01-11",{"date":95,"type":96},"2026-01-16","ACTUAL",{"date":98,"type":79},"2026-01-01",{"date":100,"type":79},"2029-12-30",{"name":5,"class":6},1]